$2.46
6.03% day before yesterday
Nasdaq, Dec 27, 10:04 pm CET
ISIN
US09060U5074
Symbol
BCDA
Sector
Industry

BioCardia Inc. Stock price

$2.46
+0.11 4.68% 1M
-0.53 17.73% 6M
-7.50 75.31% YTD
-7.74 75.88% 1Y
-35.49 93.52% 3Y
-53.49 95.60% 5Y
-159.70 98.48% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
+0.14 6.03%
ISIN
US09060U5074
Symbol
BCDA
Sector
Industry

Key metrics

Market capitalization $11.28m
Enterprise Value $7.40m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 105.71
P/S ratio (TTM) P/S ratio 161.14
P/B ratio (TTM) P/B ratio 4.04
Revenue growth (TTM) Revenue growth -87.54%
Revenue (TTM) Revenue $70.00k
EBIT (operating result TTM) EBIT $-7.76m
Free Cash Flow (TTM) Free Cash Flow $-7.31m
Cash position $4.93m
EPS (TTM) EPS $-4.16
P/S forward 112.80
EV/Sales forward 74.00
Short interest 2.65%
Show more

Is BioCardia Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

BioCardia Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast BioCardia Inc.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast BioCardia Inc.:

Buy
100%

Financial data from BioCardia Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
0.07 0.07
88% 88%
100%
- Direct Costs 0.43 0.43
8% 8%
614%
-0.35 -0.35
306% 306%
-500%
- Selling and Administrative Expenses 2.88 2.88
19% 19%
4,114%
- Research and Development Expense 4.11 4.11
53% 53%
5,871%
-7.34 -7.34
40% 40%
-10,486%
- Depreciation and Amortization 0.43 0.43
8% 8%
614%
EBIT (Operating Income) EBIT -7.76 -7.76
38% 38%
-11,091%
Net Profit -7.72 -7.72
38% 38%
-11,029%

In millions USD.

Don't miss a Thing! We will send you all news about BioCardia Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

BioCardia Inc. Stock News

Neutral
GlobeNewsWire
25 days ago
SUNNYVALE, Calif., Dec. 04, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today the successful completion of a consultation with Japan's Pharmaceutical and Medical Device Agency (PMDA) on the next steps for the submission for registration of its lead therape...
Neutral
Seeking Alpha
about 2 months ago
BioCardia, Inc. (NASDAQ:BCDA ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Miranda Peto - Investor Relations Peter Altman - President and CEO David McClung - Chief Financial Officer Conference Call Participants Joe Pantginis - H.C. Wainwright Kumar Raja - Brookline Capital Markets Operator Good afternoon, ladies and gentlemen.
Neutral
GlobeNewsWire
3 months ago
SUNNYVALE, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today that the Company has regained full compliance with the Nasdaq Capital Market's Listing Requirements as required by the Hearing Panel's (the “Panel”) decision on May 13, 2024.
More BioCardia Inc. News

Company Profile

BioCardia, Inc. operates as a clinical-stage regenerative medicine company. It develops novel therapeutics for cardiovascular diseases. The firm offers proprietary comprehensive biotherapeutic solutions for cardiovascular disease under the CardiAMP and CardiALLO brand. It operates in only one business segment, which is a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. The company was founded on January 12, 1994 and is headquartered in San Carlos, CA.

Head office United States
CEO Peter Altman
Employees 20
Founded 1994
Website www.biocardia.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today